{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-084088","form_type":"8-K/A","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2026-07-16T12:01:18+00:00","discovered_at":"2026-07-16T12:05:00.427759+00:00","generated_at":"2026-07-16T12:05:14.651683+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Edgewise closes $1.55B sale of sevasemten to Servier; pivots to cardiovascular pipeline","bullets":["Received $1.55B upfront cash; eligible for up to $1.1B in regulatory/commercial milestones.","Pro forma cash at March 31, 2026: $1.53B (up from $33.2M historical).","Pro forma net income for FY2025: $1.1355B (vs. historical net loss of $167.8M).","Company now focused on cardiovascular assets EDG-7500, EDG-15400, and EDG-003.","Transition Services Agreement with Servier: at least 18 months; $17.9M deferred liability."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-084088","json":"https://secwatch.observer/filing/0001104659-26-084088.json","markdown":"https://secwatch.observer/filing/0001104659-26-084088.md","text":"https://secwatch.observer/filing/0001104659-26-084088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465926084088/0001104659-26-084088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465926084088/tm2620181d2_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-16T12:05:14.651683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}